A Phase 1, Placebo-Controlled, Double-Blinded Study to Assess the Safety and Pharmacokinetics of Single Ascending Doses of EV68-228-N Ins Healthy Adult Volunteers
Latest Information Update: 09 May 2025
At a glance
- Drugs EV 68228 N (Primary)
- Indications Acute flaccid myelitis; Enterovirus infections
- Focus Adverse reactions; First in man
Most Recent Events
- 11 Apr 2025 Status changed from active, no longer recruiting to completed.
- 21 Mar 2025 Planned End Date changed from 3 Mar 2025 to 2 Apr 2025.
- 12 Dec 2024 Status changed from recruiting to active, no longer recruiting.